Clinical Trials Directory

Trials / Unknown

UnknownNCT02883205

Diagnosis of Fabry Disease: Impact of an Educational Brochure Intended for Cardiologist

Status
Unknown
Phase
Study type
Observational
Enrollment
50 (estimated)
Sponsor
University Hospital, Caen · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The cardiac Fabry disease are early, frequent and severe, dominated by the frequency of left ventricular hypertrophy. They are responsible for a high morbidity and mortality, reducing life expectancy of 15 to 20 years for men. Fabry disease and heart attacks are still diagnosed late. This delay in diagnosis is due to the non-specificity of clinical, electrocardiographic and echocardiographic disease, but also by a certain ignorance of this pathology in the medical community. The importance of early diagnosis of Fabry disease and heart disease is well established: enzyme replacement therapy is most effective when instituted early, before the onset of irreversible damage such as fibrosis. With the blotter, we now have a simple and robust screening tool for Fabry disease, achievable consultation. Targeted educational interventions to physicians have shown their effectiveness in improving the screening and diagnosis of rare diseases. We offer a prospective observational type before / after study, which aims to assess the value of an educational brochure for cardiologists to improve the screening and diagnosis of Fabry disease in Normandy.

Conditions

Timeline

Start date
2015-01-01
Primary completion
2016-12-01
Completion
2016-12-01
First posted
2016-08-30
Last updated
2016-08-30

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02883205. Inclusion in this directory is not an endorsement.